753.41
3.25%
23.68
プレマーケット:
751.00
-2.41
-0.32%
前日終値:
$729.73
開ける:
$735.785
24時間の取引高:
4.92M
Relative Volume:
1.53
時価総額:
$693.54B
収益:
$40.86B
当期純損益:
$8.37B
株価収益率:
139.02
EPS:
5.4193
ネットキャッシュフロー:
$-2.28B
1週間 パフォーマンス:
-7.19%
1か月 パフォーマンス:
-17.93%
6か月 パフォーマンス:
-3.80%
1年 パフォーマンス:
+26.07%
Lilly Eli Co Stock (LLY) Company Profile
LLY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
LLY | 753.41 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
NVO | 105.27 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
JNJ | 153.11 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
ABBV | 167.76 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
MRK | 97.44 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-15 | 開始されました | Wolfe Research | Outperform |
2024-10-17 | 開始されました | Bernstein | Outperform |
2024-09-13 | 再開されました | Citigroup | Buy |
2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-10-20 | 再開されました | UBS | Buy |
2023-08-09 | アップグレード | Jefferies | Hold → Buy |
2023-07-26 | 繰り返されました | Citigroup | Buy |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-05-24 | 繰り返されました | BofA Securities | Buy |
2023-05-24 | 繰り返されました | UBS | Buy |
2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-03-06 | 開始されました | Jefferies | Hold |
2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
2022-11-18 | 開始されました | Credit Suisse | Outperform |
2022-09-22 | アップグレード | UBS | Neutral → Buy |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2022-04-06 | 再開されました | Morgan Stanley | Overweight |
2022-03-10 | 開始されました | Daiwa Securities | Outperform |
2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
2021-12-17 | 開始されました | Goldman | Neutral |
2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
2021-12-16 | 繰り返されました | BofA Securities | Buy |
2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
2021-10-11 | アップグレード | Berenberg | Hold → Buy |
2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
2021-07-27 | 再開されました | Truist | Buy |
2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-11-10 | 再開されました | Bernstein | Mkt Perform |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
2020-04-21 | ダウングレード | UBS | Buy → Neutral |
2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-02-06 | 開始されました | Mizuho | Neutral |
2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2019-10-17 | 再開されました | BofA/Merrill | Buy |
2019-05-28 | 開始されました | Goldman | Buy |
2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
2019-03-12 | 開始されました | JP Morgan | Overweight |
2019-01-23 | 開始されました | UBS | Buy |
2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-10-09 | 開始されました | Guggenheim | Buy |
2018-10-01 | 繰り返されました | SunTrust | Buy |
2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters
Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8
Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks
Eli Lilly in pact for novel weight loss therapy (LLY:NYSE) - Seeking Alpha
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace
Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online
Is Novo Nordisk Stock a Buy Right Now? - The Motley Fool
Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance
Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com
Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com
Eli Lilly & Co Appoints Procter & Gamble CEO to Board - TipRanks
Eli Lilly appoints Jon Moeller to board of directors - TipRanks
Eli Lilly & Co. stock rises Tuesday, still underperforms market - MarketWatch
Eli Lilly & Co. (LLY) Announces Board Changes - StreetInsider.com
Lilly announces changes on board of directors - Yahoo Finance
Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley - Yahoo Finance
Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial - CNBC
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip? - Benzinga
Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss - TipRanks
Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund - Yahoo Finance
Lilly’s Lp(a) targeting candidate muvalaplin meets primary endpoint in Phase 2 trial - World Pharmaceutical Frontiers
Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease - OutSourcing-Pharma.com
Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters
Cramer's Lightning Round: Eli Lilly is a buy - NECN
Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Reuters
Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company
Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive
Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa
Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Benzinga
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette
Eli Lilly: positive results for tirzepatide - Marketscreener.com
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360
Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Lilly Sues HHS for Ending Planned 340B Drug Program Cash Rebates - Bloomberg Law
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):